4.7 Article

Targeted intracorneal delivery-Biodistribution of triamcinolone acetonide following topical iontophoresis of cationic amino acid ester prodrugs

Journal

INTERNATIONAL JOURNAL OF PHARMACEUTICS
Volume 525, Issue 1, Pages 43-53

Publisher

ELSEVIER SCIENCE BV
DOI: 10.1016/j.ijpharm.2017.04.030

Keywords

Corneal graft rejection; Triamcinolone acetonide; Prodrug; Iontophoresis; Intracorneal biodistribution; Full field optical coherence tomography

Funding

  1. University of Geneva
  2. Swiss Commission for Technology and Innovation [CTI 13933.2]
  3. Carigest SA

Ask authors/readers for more resources

The aim was to investigate intracorneal iontophoresis of biolabile triamcinolone acetonide (TA) amino acid ester prodrugs (TA-AA). Arginine and lysine esters of TA (TA-Arg and TA-Lys, respectively) were synthesized and characterized; quantification was performed by HPLC-UV and UHPLC-MS/MS. The aqueous solubility of the prodrugs (at pH 5.5) was similar to 1000-fold greater than TA. Anodal iontophoresis (10 min at 3 mA/cm(2)) of TA-AA was investigated using isolated porcine cornea. Although no statistically significant difference was observed in total intracorneal delivery of TA (468.25 +/- 59.70 and 540.85 +/- 79.16 nmol(TA)/cm(2), for TA-Arg and TA-Lys, respectively), the different susceptibilities of the prodrugs to hydrolysis influenced intracorneal biodistribution. Quantification of TA in twenty-five 40 mm thick corneal lamellae revealed significantly deeper penetration of TA following TA-Lys iontophoresis. Its superior resistance to hydrolysis enabled sustained electromigration into the deeper cornea suggesting judicious prodrug selection might enable targeted regioselective drug delivery. The intracorneal biodistribution following anodal iontophoresis of TA-Arg (2.3 mM; 10 min, 3 mA/cm(2)) was visualized by full field optical coherence tomography providing qualitative confirmation of the extensive intracorneal penetration of TA. Short duration iontophoresis of TA-AA prodrugs may improve deep corneal bioavailability and efficacy in vivo, constituting a single-shot treatment option for corneal allograft rejection. (C) 2017 Elsevier B. V. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available